10:48am ET
Investing
The Advantage Johnson & Johnson’s Phase 3 COVID-19 Study Has Over Rivals
The race for the COVID-19 vaccine is still very much on, and Johnson & Johnson just announced the launch of a Phase 3 trial.
Companies
/Healthcare
Johnson & Johnson
$270.00
▼ $3.14 (−1.15%) today
Markets closed · 11:51pm ET
JNJ Coverage
Page 38
3:27pm ET
Health and Healthcare
What Does a Perfect COVID-19 Vaccine Actually Mean?
The race for finding the COVID-19 vaccine is in full swing, and it has just seen one team move ahead of the others. Before getting into an actual prediction basis for knowing…
7:27pm ET
Health and Healthcare
As CDC Issues Notice, Stock Market Bets Which Company Gets First COVID-19 Vaccine FDA Approval
America and the rest of the world is getting ready for a vaccine that will help protect public health against the COVID-19 pandemic. The societal impact of the coronavirus has changed many…
8:46am ET
Health and Healthcare
3 COVID-19 Vaccine Trials Are Now in Phase 3, With More on the Way
Three U.S. COVID-19 vaccine trials are now in Phase 3 studies. All three appear to have some serious benefits, but none are approved yet.
11:33am ET
Health and Healthcare
Johnson & Johnson’s Newest Multibillion Dollar Acquisition
After Momenta Pharmaceuticals announced that it would be acquired by pharmaceutical giant Johnson & Johnson, the biotechnology company's shares soared on Wednesday.
Chris Lange 11:54am ET
Health and Healthcare
Johnson & Johnson Takes the Next Big Step in Fighting COVID-19
Johnson & Johnson has announced that it will launch its human study for its lead vaccine candidate in the United States and Belgium.
Chris Lange 1:42pm ET
Health and Healthcare
Beyond COVID-19, Credit Suisse Shows Its Top Health Care Recovery Stock Picks
Credit Suisse has assembled its favorite health care recovery stocks for a recovering base of elective surgeries and for the risk of rising hospitalizations that go well beyond COVID-19.
7:36am ET
Investing
Stock Dividend Yields the Highest Versus Bonds Since 1955: 5 to Buy Now for Income
If you are a bond and income investor now, times are grim. One analyst says that the best income portfolio now very well may be a collection of high-quality stocks that pay…
12:32pm ET
Investing
8 Blue Chip Stocks to Buy Ahead of Earnings for Big Upside
Many investors feel like the key stocks in the market have simply gotten away from them, but those fears are perhaps misguided, according to some key analysts.
9:09am ET
Investing
Top Analyst Upgrades and Downgrades: AMD, Amgen, Dropbox, EOG, Gilead, J&J, Microsoft, Newmont, Starbucks, Valero and More
Stocks were looking for direction on Monday ahead of this week’s earnings deluge. With an election coming up and with what is still a very deep recession, investors need to be considering…
10:57am ET
Health and Healthcare
Johnson & Johnson’s Impressive Quarter, Still Held Back by One Segment
Johnson & Johnson released better than expected quarterly results and guidance before the markets opened on Thursday.
Chris Lange 7:05am ET
Investing
Delta Air, Johnson & Johnson, Netflix, Pepsi and More Major Earnings This Week
Here, 24/7 Wall St. offers a preview of what to expect from Delta Air Lines, Netflix, PepsiCo and some of the other most anticipated quarterly results due this week.
11:18am ET
Health and Healthcare
Johnson & Johnson Accelerates Its COVID-19 Vaccine Hopes
Johnson & Johnson has announced that it will accelerate initiation of its early stage first-in-human clinical trial for the treatment of COVID-19. Shares got a mild boost on Wednesday from the news.
Chris Lange 7:26am ET
Investing
5 Dividend Aristocrat Stocks to Buy That Could Weather Another Brutal Sell-Off
These five very conservative Dividend Aristocrat stocks may offer nervous investors some shelter from the storm if markets head south again.
7:32am ET
Investing
20 Bold Companies Raising Dividends Right Into the Recession
Here are 20 bold companies that have defied the odds by raising their dividends, after already knowing they were facing a very deep recession.